MCID: MMB011
MIFTS: 57

Membranous Nephropathy

Categories: Rare diseases, Nephrological diseases

Aliases & Classifications for Membranous Nephropathy

MalaCards integrated aliases for Membranous Nephropathy:

Name: Membranous Nephropathy 57 12 53 29
Membranous Glomerulonephritis 12 53 15 73
Idiopathic Membranous Glomerulonephritis 59 6 73
Membranous Nephropathy, Susceptibility to 57 13
Idiopathic Membranous Nephropathy 53 55
Glomerulonephritis, Membranous 53 44
Extramembranous Glomerulonephritis 53
Nephropathy Membranous 55
Membranous Gn 53
Mbnp 57
Mgn 53

Classifications:

Orphanet: 59  
Rare renal diseases


External Ids:

OMIM 57 614692
Disease Ontology 12 DOID:10976
ICD10 33 N03.2
MeSH 44 D015433
NCIt 50 C34645
SNOMED-CT 68 197710000 77182004
Orphanet 59 ORPHA97560
ICD10 via Orphanet 34 N04.2
UMLS via Orphanet 74 C0086445

Summaries for Membranous Nephropathy

OMIM : 57 Membranous nephropathy, a major cause of the nephrotic syndrome in adults, is characterized by the presence of glomerular deposits that typically contain immunoglobulin and complement components. Two major antigens, both of which are membrane glycoproteins, have been identified in human membranous nephropathy. Neutral endopeptidase (MME; 120520) is the alloantigen involved in membranous nephropathy in neonates whose mothers have a deficiency of this enzyme. The second is the M-type phospholipase A2 receptor (PLA2R1; 604939), the first antigen identified in adults with idiopathic membranous nephropathy, which is generally considered to be an autoimmune disease. In addition, autoantibodies against aldose reductase (AKR1B1; 103880), mitochondrial superoxide dismutase-2 (SOD2; 147460), and THSD7A (612249) have been found in serum and glomeruli from patients with idiopathic membranous nephropathy. Familial occurrence has been noted by Short et al. (1984) and Bockenhauer et al. (2008) (summary by Stanescu et al., 2011 and Tomas et al., 2014). (614692)

MalaCards based summary : Membranous Nephropathy, also known as membranous glomerulonephritis, is related to focal segmental glomerulosclerosis 1 and focal segmental glomerulosclerosis. An important gene associated with Membranous Nephropathy is MME (Membrane Metalloendopeptidase), and among its related pathways/superpathways are NF-kappaB Signaling and Tuberculosis. The drugs Angiotensin II and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and neutrophil, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

NIH Rare Diseases : 53 Membranous nephropathy is a kidney disease characterized by inflammation of the structures inside the kidney that help filter wastes and fluids. When the glomerular basement membrane becomes thickened, it does not work normally, allowing large amounts of protein to be lost in the urine. Symptoms develop gradually and may include swelling, fatigue, weight gain, and high blood pressure. In many cases, the underlying cause of membranous nephropathy is not known. Some cases are associated with other conditions (lupus), infections (hepatitis B and C), cancer or as a side effect of certain medications. The goal of treatment is to reduce symptoms and slow the progression of the disease. 

Wikipedia : 76 Membranous glomerulonephritis (MGN) is a slowly progressive disease of the kidney affecting mostly... more...

Related Diseases for Membranous Nephropathy

Diseases in the Membranous Nephropathy family:

Congenital Membranous Nephropathy Due to Maternal Anti-Neutral Endopeptidase Alloimmunization

Diseases related to Membranous Nephropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 194)
# Related Disease Score Top Affiliating Genes
1 focal segmental glomerulosclerosis 1 31.2 CD2AP NPHS1 NPHS2
2 focal segmental glomerulosclerosis 30.4 ACE ALB CD2AP NPHS1 NPHS2
3 microvascular complications of diabetes 3 30.4 ACE ALB NPHS1
4 membranoproliferative glomerulonephritis 30.2 ALB C3 CD79A NPHS1
5 nephrotic syndrome 30.2 ALB B2M CD2AP NPHS1 NPHS2
6 glomerulonephritis 29.8 ALB C3 CD79A LRP2 NPHS1 NPHS2
7 iga glomerulonephritis 28.9 ACE ALB CD2AP CD79A NPHS1 NPHS2
8 chronic kidney failure 28.5 ACE ALB B2M CD79A NPHS1 NPHS2
9 kidney disease 27.8 ACE ALB B2M C3 CD2AP CD79A
10 alport syndrome and thin basement membrane nephropathy 12.2
11 anti-basement membrane glomerulonephritis 12.1
12 congenital membranous nephropathy due to maternal anti-neutral endopeptidase alloimmunization 12.0
13 hematuria, benign familial 11.9
14 goodpasture syndrome 11.1
15 familial idiopathic steroid-resistant nephrotic syndrome with minimal changes 11.0 NPHS1 NPHS2
16 sporadic idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis 10.9 CD2AP NPHS2
17 kidney hypertrophy 10.8 ALB NPHS1 NPHS2
18 atrial septal defect 3 10.7 CD2AP NPHS1 NPHS2
19 familial nephrotic syndrome 10.7 CD2AP NPHS1 NPHS2
20 nephrotic syndrome, type 1 10.7 CD2AP NPHS1 NPHS2
21 cork-handlers' disease 10.7 ALB CD79A
22 ostertagiasis 10.7 ALB CD79A
23 denys-drash syndrome 10.7 CD2AP NPHS1 NPHS2
24 dermatitis, atopic, 3 10.7 ALB CD79A
25 frasier syndrome 10.7 CD2AP NPHS1 NPHS2
26 subacute cutaneous lupus erythematosus 10.7 ACE TNF
27 skin sarcoidosis 10.6 ACE TNF
28 granulomatous dermatitis 10.6 ACE TNF
29 rheumatic heart disease 10.6 ACE HLA-DQA1 TNF
30 precursor t-lymphoblastic lymphoma/leukemia 10.6 CD79A MME
31 pyelonephritis 10.6 ACE ALB TNF
32 encapsulated thymoma 10.5 CD79A MME
33 precursor lymphoblastic lymphoma/leukemia 10.5 CD79A MME
34 hypersensitivity reaction type iii disease 10.5 ALB C3 CD79A
35 glucose metabolism disease 10.5 ACE ALB TNF
36 immunodeficiency 43 10.5 ALB B2M
37 pneumocystosis 10.5 ALB CD79A TNF
38 arteries, anomalies of 10.5 ACE ALB TNF
39 protein-energy malnutrition 10.4 ALB CD79A TNF
40 burns 10.4 ALB TNF
41 keratoconjunctivitis sicca 10.4 ALB CD79A TNF
42 root caries 10.4 ALB CD79A
43 acquired metabolic disease 10.4 ACE ALB TNF
44 guillain-barre syndrome 10.4 ALB CD79A TNF
45 toxoplasmosis 10.4 CD79A HLA-DQA1 TNF
46 obstructive jaundice 10.4 ALB CD79A TNF
47 hypersensitivity reaction type iv disease 10.4 ACE CD79A TNF
48 primary bacterial infectious disease 10.4 ALB CD79A TNF
49 intestinal disease 10.4 ALB CD79A TNF
50 schistosomiasis 10.4 ALB CD79A TNF

Graphical network of the top 20 diseases related to Membranous Nephropathy:



Diseases related to Membranous Nephropathy

Symptoms & Phenotypes for Membranous Nephropathy

Clinical features from OMIM:

614692

MGI Mouse Phenotypes related to Membranous Nephropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.1 ACE ALB B2M C3 CD2AP CD79A
2 endocrine/exocrine gland MP:0005379 10.02 ACE ALB B2M C3 CD2AP HLA-DQA1
3 hematopoietic system MP:0005397 10.02 CD79A HLA-DQA1 LRP2 PECAM1 TNF VTN
4 immune system MP:0005387 9.9 CD2AP CD79A HLA-DQA1 LRP2 MME PECAM1
5 liver/biliary system MP:0005370 9.56 ACE ALB B2M C3 CD79A MME
6 renal/urinary system MP:0005367 9.32 LRPAP1 NPHS1 NPHS2 PECAM1 ACE ALB

Drugs & Therapeutics for Membranous Nephropathy

Drugs for Membranous Nephropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4,Phase 3,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
3
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
4
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
5
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 104987-11-3 445643 439492
6
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
7
Entecavir Approved, Investigational Phase 4,Not Applicable 142217-69-4 153941
8 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Angiotensin II Type 1 Receptor Blockers Phase 4,Not Applicable
12 Angiotensin Receptor Antagonists Phase 4,Phase 3,Not Applicable
13 Angiotensinogen Phase 4,Phase 3,Not Applicable
14 Antihypertensive Agents Phase 4,Not Applicable
15 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
17 Antifungal Agents Phase 4,Phase 3,Phase 2
18 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
20 Antitubercular Agents Phase 4,Phase 3,Phase 2
21 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
22 Cyclosporins Phase 4,Phase 3,Phase 2
23 Dermatologic Agents Phase 4,Phase 3,Phase 2
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
25 Adrenocorticotropic Hormone Phase 4,Phase 2,Phase 1
26 beta-endorphin Phase 4,Phase 2,Phase 1
27 Melanocyte-Stimulating Hormones Phase 4,Phase 2,Phase 1
28 Immunoglobulin A Phase 4,Phase 2,Not Applicable
29 Antiviral Agents Phase 4,Phase 1,Phase 2,Not Applicable
30 Endorphins Phase 4
31 Neurotransmitter Agents Phase 4,Phase 3
32 Tripterygium Nutraceutical Phase 4,Not Applicable
33 Deflazacort Approved, Investigational Phase 3 14484-47-0
34
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
35
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
36
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 50-18-0, 6055-19-2 2907
37
rituximab Approved Phase 2, Phase 3,Phase 3,Early Phase 1 174722-31-7 10201696
38
Prednisone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Not Applicable 53-03-2 5865
39
Chlorambucil Approved Phase 3 305-03-3 2708
40
Serine Approved, Nutraceutical Phase 3 56-45-1 5951
41 Methylprednisolone acetate Phase 3,Phase 2
42 Methylprednisolone Hemisuccinate Phase 3,Phase 2
43 Prednisolone acetate Phase 3,Phase 2
44 Prednisolone hemisuccinate Phase 3,Phase 2
45 Prednisolone phosphate Phase 3,Phase 2
46 Antiemetics Phase 2, Phase 3,Phase 3
47 Anti-Inflammatory Agents Phase 2, Phase 3,Phase 3,Not Applicable
48 Autonomic Agents Phase 2, Phase 3,Phase 3
49 Gastrointestinal Agents Phase 2, Phase 3,Phase 3,Not Applicable
50 glucocorticoids Phase 2, Phase 3,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
2 To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) Completed NCT00518219 Phase 4 TW
3 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
4 Adrenocorticotropic Hormone in Membranous Nephropathy Recruiting NCT03025828 Phase 4 ACTHar
5 Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Recruiting NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
6 Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN) Recruiting NCT03062813 Phase 4 Tacrolimus &entecavir;placebo & entecavir
7 Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Active, not recruiting NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
8 Acthar for Treatment of Post-transplant FSGS Not yet recruiting NCT02399462 Phase 4 Acthar
9 Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
10 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Withdrawn NCT01926054 Phase 4 Acthar gel
11 Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy Unknown status NCT01282073 Phase 3 Mycophenolate mofetil, low dose steroid;Cyclosporin, low dose steroid
12 Rituximab in Membranous Nephropathy Completed NCT00425217 Phase 2, Phase 3 Rituximab
13 Mycophenolate Mofetil in Membranous Nephropathy Completed NCT00135967 Phase 2, Phase 3 mycophenolate mofetil orally 1000 mg twice a day (BID);prednisone 0,5 mg/kg orally on alternate days;intravenous (i.v.) methylprednisolone 1000 mg, total 9
14 Treatment of Patients With Idiopathic Membranous Nephropathy Completed NCT00135954 Phase 3 Cyclophosphamide and steroids
15 Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental Completed NCT00404833 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and chlorambucil
16 Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Completed NCT00362531 Phase 2, Phase 3 tacrolimus combined with prednisone
17 A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis Completed NCT00404794 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and tacrolimus
18 Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy Recruiting NCT01955187 Phase 3 TACROLIMUS;RITUXIMAB;METHYLPREDNISOLONE;CYCLOPHOSPHAMIDE
19 Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Recruiting NCT03018535 Phase 3 Rituximab;Methylprednisolone;Cyclophosphamide
20 Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy Active, not recruiting NCT01508468 Phase 3 symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
21 MEmbranous Nephropathy Trial Of Rituximab Active, not recruiting NCT01180036 Phase 2, Phase 3 Rituximab;Cyclosporine
22 Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Active, not recruiting NCT02077868 Phase 3 MGN1703 treatment
23 A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy Unknown status NCT02173106 Phase 2 steroid & Cyclosporin
24 Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy Completed NCT00694863 Phase 2 tetracosactide hexacetaat
25 Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC Completed NCT02200081 Phase 2 MGN1703
26 Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy Completed NCT00050713 Phase 2 Sirolimus
27 Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma Completed NCT01208194 Phase 2 MGN1703;Placebo
28 A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy Completed NCT01093157 Phase 1, Phase 2 Adrenocorticotrophic hormone ACTH
29 Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection Completed NCT02443935 Phase 1, Phase 2 MGN1703;MGN1703
30 Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV Completed NCT02690103 Phase 2 pegylated IFN;Ribavirin
31 A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy Completed NCT01610492 Phase 2 belimumab
32 Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy Recruiting NCT03255447 Phase 2
33 Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN) Recruiting NCT03285711 Phase 2 Filgotinib;GS-9876;Filgotinib placebo;GS-9876 placebo
34 Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy Recruiting NCT00977977 Phase 2 Rituximab Infusion;Oral Cyclosporine
35 Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 Recruiting NCT02682407 Phase 2
36 Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies Recruiting NCT03453619 Phase 2 APL-2
37 A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET) Active, not recruiting NCT01265368 Phase 1, Phase 2
38 Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy Withdrawn NCT01762852 Phase 2 Belimumab 10 mg;Placebo
39 A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703 Completed NCT01982747 Phase 1 MGN-Placebo;Placebo-MGN
40 Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy Completed NCT00805753 Phase 1 ACTH
41 A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases Completed NCT02639260 Phase 1 N-acetyl-mannosamine (ManNAc)
42 Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies Recruiting NCT02668770 Phase 1 MGN1703;Ipilimumab
43 Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus Terminated NCT00479622 Phase 1 TRU-015
44 Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy Unknown status NCT01845688 Not Applicable Losartan Tablets & QingReMoShen Granule;Losartan Tablets & Placebo Granule
45 Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy Unknown status NCT01799460 The Comprehensive Treatment Regimen of Traditional Chinese Medicine;The immunosuppressive agents
46 Phospholipase A2 Receptor (PLA2R1) Autoantibodies in Membranous Nephropathy in Kidney Transplantation Unknown status NCT01897961 Not Applicable
47 Study on the Therapeutic Effect of TCM Treatment for MDR MN Unknown status NCT02610595 Not Applicable Jianpixiaozhong particles and Wuse Dietotherapy
48 Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization Unknown status NCT00199628
49 Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies Unknown status NCT00456118
50 The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy Completed NCT00983034 Not Applicable lansoprazole, amoxicillin, clarithromycin

Search NIH Clinical Center for Membranous Nephropathy

Cochrane evidence based reviews: glomerulonephritis, membranous

Genetic Tests for Membranous Nephropathy

Genetic tests related to Membranous Nephropathy:

# Genetic test Affiliating Genes
1 Membranous Nephropathy 29

Anatomical Context for Membranous Nephropathy

MalaCards organs/tissues related to Membranous Nephropathy:

41
Kidney, Bone, Neutrophil, Endothelial, Liver, Bone Marrow, T Cells

Publications for Membranous Nephropathy

Articles related to Membranous Nephropathy:

(show top 50) (show all 926)
# Title Authors Year
1
The Unpredictability of Idiopathic Membranous Nephropathy: An Illustrative Case Report. ( 29928646 )
2018
2
Anti-PLA2R antibody in a secondary cause of membranous nephropathy. ( 29250915 )
2018
3
Membranous glomerulonephritis with an LMNA mutation. ( 29349732 )
2018
4
Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti-HCV therapy (ledipasvir/sofosbuvir). ( 29968947 )
2018
5
Midterm Outcome of Kidney Transplantation From Donors With Thin Basement Membrane Nephropathy. ( 29334529 )
2018
6
Urine anti-PLA2R antibody is a novel biomarker of idiopathic membranous nephropathy. ( 29416596 )
2018
7
Membranous Nephropathy: Approaches to Treatment. ( 29852477 )
2018
8
A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up. ( 29924035 )
2018
9
Clinicopathological study of de novo membranous nephropathy of 'stage 0' after kidney transplantation. ( 29968407 )
2018
10
Membranous nephropathy associated with pregnancy: an anti-phospholipase A2 receptor antibody-positive case report. ( 29349731 )
2018
11
The clinicopathological features of patients with membranous nephropathy. ( 29403303 )
2018
12
A Cohort Study of Incidences and Risk Factors for Thromboembolic Events in Patients with Idiopathic Membranous Nephropathy. ( 29976278 )
2018
13
Liddle's-like syndrome associated with nephrotic syndrome secondary to membranous nephropathy: the first case report. ( 29792170 )
2018
14
Management of Membranous Nephropathy in the PLA<sub>2</sub>R Era. ( 29378770 )
2018
15
Primary membranous nephropathy presenting with crescentic glomerulonephritis 25 years after initial presentation: A case reporta8c. ( 29932409 )
2018
16
High urinary interleukin-8 levels is associated with poor prognosis in idiopathic membranous nephropathy. ( 29415357 )
2018
17
Acquired von Willebrand Syndrome Complicating Nephrotic Syndrome: A Case of a Patient With Membranous Nephropathy. ( 29568223 )
2018
18
Concurrent Presentation of Thrombotic Thrombocytopenic Purpura and Membranous Nephropathy. ( 29725652 )
2018
19
Correlation and discrepancy of phospholipase A2 receptor staining in membranous nephropathy in paraffin-embedded kidney biopsies. ( 29970727 )
2018
20
Concurrent isolated IgG2-positive membranous nephropathy and malignant B-cell lymphoma. ( 29766466 )
2018
21
Mannose-Binding Lectin2 Gene Polymorphism and IgG4 in Membranous Nephropathy. ( 29439276 )
2018
22
Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy. ( 29423201 )
2018
23
Temporal Association Between PLA2R Antibodies and Clinical Outcomes in Primary Membranous Nephropathy. ( 29340324 )
2018
24
Urine proteomics of primary membranous nephropathy using nanoscale liquid chromatography tandem mass spectrometry analysis. ( 29445323 )
2018
25
Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A<sub>2</sub> receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis. ( 29792176 )
2018
26
Human anti-thrombospondin type 1 domain-containing 7A antibodies induce membranous nephropathy through activation of lectin complement pathway. ( 29769410 )
2018
27
Expression of phospholipase A2 receptor and IgG4 in patients with membranous nephropathy. ( 29881283 )
2018
28
Combined membranous nephropathy and tubulointerstitial nephritis as a rare renal manifestation of IgG4-related disease: a case-based literature review. ( 29388171 )
2018
29
Idiopathic membranous nephropathy in patients with diabetes mellitus: a diagnostic and therapeutic quandary! ( 29423200 )
2018
30
Diagnostic Test Accuracy of Serum Anti-PLA2R Autoantibodies and Glomerular PLA2R Antigen for Diagnosing Idiopathic Membranous Nephropathy: An Updated Meta-Analysis. ( 29755981 )
2018
31
Membranous Nephropathy in a Patient With Common Variable Immune Deficiency. ( 29854983 )
2018
32
Hemizygous Fabry disease associated with membranous nephropathy: A rare case reporta8c. ( 29792392 )
2018
33
The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial. ( 29441742 )
2018
34
The prognostic value of phospholipase A2 receptor autoantibodies on spontaneous remission for patients with idiopathic membranous nephropathy: A meta-analysis. ( 29879066 )
2018
35
BAFF and APRIL expression as an autoimmune signature of membranous nephropathy. ( 29423047 )
2018
36
Segmental membranous nephropathy with severe IgG3 deposition. ( 29744961 )
2018
37
Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience. ( 29942496 )
2018
38
The skin-kidney connection: bullous pemphigoid associated with acute allograft rejection and membranous nephropathy. ( 29445491 )
2018
39
Polyarteritis Nodosa and Membranous Glomerulonephritis: Two Simultaneous Extrahepatic Manifestations of Hepatitis B. ( 29965852 )
2018
40
Recurrence of membranous nephropathy three weeks' postrenal transplant: A surprise in store. ( 29970749 )
2018
41
Different Effects of Tolvaptan in Patients with Idiopathic Membranous Nephropathy with Nephrotic Syndrome. ( 28090051 )
2017
42
Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy. ( 28904360 )
2017
43
A rare case of concurrent myeloperoxidase anti-neutrophil cytoplasmic antibody (MPO-ANCA)-associated necrotising and crescentic glomerulonephritis and membranous glomerulonephritis. ( 27931720 )
2017
44
Coexistence of Anti-Glomerular Basement Membrane Glomerulonephritis and Membranous Nephropathy in a Female Patient with Preserved Renal Function. ( 29269610 )
2017
45
Successful therapy with mycophenolic acid inA a membranous glomerulonephritis due toA Kimura diseasea8c. ( 28853699 )
2017
46
Hypocomplementemic Urticarial Vasculitis Syndrome with Membranous Nephropathy: Case Report. ( 29115092 )
2017
47
A Heterologous Model of Thrombospondin Type 1 Domain-Containing 7A-Associated Membranous Nephropathy. ( 28814510 )
2017
48
Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents. ( 28877834 )
2017
49
Analysis of PLA2R1 and HLA-DQA1 sequence variants in Japanese patients with idiopathic and secondary membranous nephropathy. ( 28849274 )
2017
50
Inhibition of tumor necrosis factor signaling attenuates renal immune cell infiltration in experimental membranous nephropathy. ( 29340080 )
2017

Variations for Membranous Nephropathy

ClinVar genetic disease variations for Membranous Nephropathy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MME NM_000902.3(MME): c.1342C> T (p.Arg448Ter) single nucleotide variant Pathogenic rs149905705 GRCh38 Chromosome 3, 155144383: 155144383
2 MME NM_000902.3(MME): c.1342C> T (p.Arg448Ter) single nucleotide variant Pathogenic rs149905705 GRCh37 Chromosome 3, 154862172: 154862172

Expression for Membranous Nephropathy

Search GEO for disease gene expression data for Membranous Nephropathy.

Pathways for Membranous Nephropathy

Pathways related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.07 B2M CD2AP CD79A PECAM1 TNF
2 11.81 C3 HLA-DQA1 PLA2R1 TNF
3 11.48 HLA-DQA1 MME TNF
4 10.89 CD2AP MME NPHS1 NPHS2 VTN
5 10.55 CD2AP NPHS1 NPHS2

GO Terms for Membranous Nephropathy

Cellular components related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 ACE ALB B2M C3 PECAM1 SERPINB7
2 plasma membrane GO:0005886 9.83 ACE B2M C3 CD2AP CD79A HLA-DQA1
3 membrane raft GO:0045121 9.73 CD79A NPHS2 PECAM1 TNF
4 external side of plasma membrane GO:0009897 9.55 ACE B2M CD79A LRP2 TNF
5 endosome lumen GO:0031904 9.46 LRP2 LRPAP1
6 extracellular exosome GO:0070062 9.44 ACE ALB B2M C3 CD2AP LRP2
7 slit diaphragm GO:0036057 9.4 NPHS1 NPHS2
8 rough endoplasmic reticulum lumen GO:0048237 9.26 LRPAP1 VTN
9 extracellular region GO:0005576 10.07 ACE ALB B2M C3 LRPAP1 PLA2R1

Biological processes related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.63 B2M C3 HLA-DQA1 TINAG TNF VTN
2 amyloid-beta metabolic process GO:0050435 9.4 ACE MME
3 replicative senescence GO:0090399 9.37 MME PLA2R1
4 angiotensin maturation GO:0002003 9.32 ACE MME
5 amyloid-beta clearance GO:0097242 9.26 C3 MME
6 receptor-mediated endocytosis GO:0006898 9.02 ALB LRP2 PLA2R1 TINAG VTN
7 regulation of receptor-mediated endocytosis GO:0048259 8.96 CD2AP LRPAP1

Molecular functions related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 polysaccharide binding GO:0030247 9.16 TINAG VTN
2 drug binding GO:0008144 9.13 ACE ALB LRP2
3 exopeptidase activity GO:0008238 8.62 ACE MME

Sources for Membranous Nephropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....